Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases.
Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases.
复制标题
DOI：
10.1016/j.cgh.2018.12.014
复制
发表时间：
2019-09
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
幽门螺杆菌可诱导免疫耐受，并与免疫介导性疾病(如自身免疫性和炎症性肠病)的风险较低有关。我们的目的是确定幽门螺杆菌感染的治疗对自身免疫性疾病和IBD发生率的影响。我们从台湾国家健康保险研究资料库收集资料，研究对象为18岁以下且未被诊断为自身免疫性疾病或IBD的患者。有幽门螺杆菌感染(PUD+HPRx)的消化性溃疡患者(PUD+HPRx)、未接受Hp治疗的PUD(PUD-HPRx)、接受头孢菌素治疗的尿路感染(UTI)或无PUD的患者(对照组)在年龄、性别、保险和Charlson共病指数评分方面匹配。在我们2005年收集的100万名患者的数据中，我们纳入了79,181名患者。我们比较了幽门螺杆菌感染的治疗对自身免疫或IBD风险的影响，发现PUD+HPRx对自身免疫或IBD的调整风险(AHR，2.36)高于PUD-HPRx(AHR，1.91)或UTI(AHRS，1.71)(P<；.001)。仅靠抗生素治疗并不能完全解释自身免疫性疾病风险的增加，因为PUD+HPRx的AHR高于UTI(P<；.001)。在PUD+HPRx队列中观察到死亡率有小幅但显著的增加(AHR，1.11；P=.001)。在对台湾国家健康保险研究数据库的数据进行分析后，我们发现，治疗幽门螺杆菌感染与自身免疫性疾病(包括IBD)风险的显著增加有关。
Helicobacter pylori induces immune tolerance and is associated with a lower risk for immune-mediated disorders, such as autoimmune and inflammatory bowel diseases (IBD). We aimed to determine the effects of treatment for H pylori infection on the incidence of autoimmune disease and IBD. We collected data from the National Health Insurance Research Database in Taiwan on patients younger than 18 years old without a prior diagnosis of autoimmune disease or IBD. Patients with peptic ulcer disease (PUD) with treatment of H pylori infection (PUD+HPRx), PUD without H pylori treatment (PUD–HPRx), a urinary tract infection (UTI) treated with cephalosporin, or without PUD (controls) were matched for age, sex, insurance, and Charlson’s comorbidity index score. Of the 1 million patients we collected data from in 2005, we included 79,181 patients in the study. We compared the effects of treatment for H pylori infection on the risk of autoimmunity or IBD and found that PUD+HPRx has the highest adjusted hazard risk (aHR) for autoimmunity or IBD (aHR, 2.36), compared to PUD–HPRx (aHR, 1.91) or UTI (aHRs, 1.71) (P<.001). The increased risk of autoimmune disease was not completely accounted for by antibiotic therapy alone, because PUD+HPRx had a higher aHR than UTI (P<.001). A small but significant increase in mortality was observed in the PUD+HPRx cohort (aHR, 1.11; P=.001). In an analysis of data from the National Health Insurance Research Database in Taiwan, we found that treatment for H pylori infection is associated with a significant increase in the risk for autoimmune disease, including IBD.
登录
查看更多内容
影响因子：
29.4
作者：
Ng, Siew C.;Tang, Whitney;Chan, Francis K. L.
通讯作者：
Chan, Francis K. L.
DOI：
10.1086/590158
发表时间：
2008-08-15
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Chen Y;Blaser MJ
通讯作者：
Blaser MJ
影响因子：
4.3
作者：
Papamichael, Konstantinos;Konstantopoulos, Panagiotis;Mantzaris, Gerassimos J.
通讯作者：
Mantzaris, Gerassimos J.
影响因子：
29.4
作者：
Rad, Roland;Brenner, Lena;Prinz, Christian
通讯作者：
Prinz, Christian
DOI：
10.7883/yoken1952.51.13
发表时间：
1998-11-01
期刊：
JAPANESE JOURNAL OF MEDICAL SCIENCE & BIOLOGY
影响因子：
--
作者：
Lin, CW;Chang, YS;Cheng, KS
通讯作者：
Cheng, KS